Treace Medical Concepts Analyst Ratings
BTIG Maintains Treace Medical Concepts(TMCI.US) With Hold Rating
Truist Financial Maintains Treace Medical Concepts(TMCI.US) With Hold Rating, Raises Target Price to $7
Analysts Offer Insights on Healthcare Companies: Merus (MRUS), Fresenius Medical Care (FMS) and Treace Medical Concepts (TMCI)
Treace Medical Concepts (TMCI) Gets a Hold From BTIG
Truist Financial Maintains Treace Medical Concepts(TMCI.US) With Hold Rating, Cuts Target Price to $6
Treace Medical Concepts Analyst Ratings
Truist Lowers Price Target on Treace Medical Concepts to $6 From $7.50, Keeps Hold Rating
Morgan Stanley Maintains Treace Medical Concepts(TMCI.US) With Hold Rating, Maintains Target Price $7.5
Maintaining Hold on Treace Medical Concepts Amidst Stable Growth and Anticipated Product Launches
Treace Medical Concepts Analyst Ratings
Truist Financial Sticks to Their Hold Rating for Treace Medical Concepts (TMCI)
Treace Medical Concepts Analyst Ratings
Morgan Stanley Raises Price Target on Treace Medical Concepts to $8 From $5.50, Keeps Equalweight Rating
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Treace Medical Concepts (TMCI) and Veeva Systems (VEEV)
UBS Downgrades Treace Medical, Cites Increasing Competition
UBS: Downgraded the Treace Medical Concepts (TMCI.US) rating from buy to neutral, and adjust the target price from $16.00 to $6.50.
Treace Medical Concepts Analyst Ratings
UBS Downgrades Treace Medical Concepts to Neutral From Buy, Cuts Price Target to $6.50 From $16
Treace Medical Concepts Analyst Ratings